News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron Pharmaceuticals, Inc. (REGN) Announces January 2013 Investor Conference Presentations



12/20/2012 8:08:04 AM

TARRYTOWN, N.Y., Dec. 20, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:

  • Goldman Sachs Healthcare CEOs Unscripted:  A View from the Top on Thursday, January 3, 2013.  The session is scheduled for 3:15 p.m. Eastern Time.
  • 31st Annual J. P. Morgan Healthcare Conference on Tuesday, January 8, 2013.  The presentation is scheduled for 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:




Michael Aberman, M.D.                       

Peter Dworkin

Investor Relations                                

Corporate Communications                           

914.847.7799                                           

914.847.7640             

michael.aberman@regeneron.com             

peter.dworkin@regeneron.com

 

SOURCE Regeneron Pharmaceuticals, Inc.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES